Super League Enterprise Inc
Media
Super League Enterprise Inc (SLE) Stock News
The latest SLE headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems presented new clinical data at SLEEP 2026 demonstrating the effectiveness of its Inspire V hypoglossal nerve stimulation system for obstructive sleep apnea treatment. Key findings include significant reductions in hypoxic burden, improved cardiovascular outcomes compared to CPAP therapy, and higher patient adherence rates. The company also published studies identifying predictors for therapy eligibility and presented results from its 5,000-patient ADHERE registry showing 62% median AHI reduction.
- GlobeNewswire Inc.·
Sleep.ai to Present 10 Scientific Studies at SLEEP 2026, Highlighting Advances in Digital Sleep Intelligence and Product Validation
Sleep.ai announced that 10 scientific studies will be presented at SLEEP 2026, including three original AI/ML analyses on smartphone-based sleep detection and sleep apnea prediction, plus seven partner validation studies on sleep-related products. The presentations underscore Sleep.ai's commitment to evidence-based sleep innovation, leveraging over one billion hours of sleep data and 250+ scientific studies.
- GlobeNewswire Inc.·
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson & Johnson announced that nipocalimab, an FcRn blocker, met its primary endpoint in the Phase 2 JASMINE study by significantly reducing systemic lupus erythematosus (SLE) disease activity at 24 weeks and sustained improvements through 52 weeks. The drug demonstrated greater efficacy in autoantibody-positive patients (80% of SLE population) with a favorable safety profile. The Phase 3 GARDENIA study is ongoing, and nipocalimab received Fast Track Designation from the FDA in January 2026.